Lipoprotein(a) and cardiovascular disease

Eight years after questioning how Lp(a) actually causes harm, the same two researchers return with a definitive account — arriving, deliberately, just as the first drugs designed to lower it reach their make-or-break trials.

The review’s through-line is structure explaining disease. Lp(a) is an LDL-like particle with an extra protein, apo(a), whose repeating “kringle” domains vary in number from person to person — and that genetic variation, not lifestyle, sets blood levels. More than 90% of where your Lp(a) lands is fixed by the LPA gene. The mechanistic heart of the piece is oxidized phospholipids: Lp(a) carries the lion’s share of these inflammatory molecules in the blood, and the authors argue they mediate nearly all of Lp(a)’s artery-damaging and valve-calcifying effects. The danger, in other words, is the inflammatory cargo, not just the cholesterol.

That explains two clinically crucial facts: Lp(a) risk is independent of LDL, and aggressively lowering LDL does nothing to address it. Statins don’t lower Lp(a) (and may nudge it up); PCSK9 inhibitors manage only a modest cut. The new RNA-directed drugs — pelacarsen, olpasiran, lepodisiran — achieve 70–90% reductions, and the oral agent muvalaplin around 65% by blocking particle assembly.

The honest caveats are front and center: the receptor that clears Lp(a) is still unidentified, and no trial has yet proven that lowering Lp(a) prevents events. The authors disclose industry ties to the drug developers.

We rate the evidence high — an authoritative, 161-reference synthesis from the field’s leading laboratory, integrating molecular biology, genetics, and the trial landscape. Its clinical significance is equally high: it is the reference clinicians will use to interpret the outcome trials (Lp(a)HORIZON, OCEAN(a), ACCLAIM-Lp(a)) that will determine whether roughly a fifth of patients with elevated Lp(a) finally have a treatment.